Company Overview and News

 
Panacea Biotec Limited - Disclosure under SEBI Takeover Regulations

2018-04-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Serum Institute Of India sells 31.57 lakh shares of Panacea Biotec

2018-03-27 moneycontrol
On March 26, 2018 Adar Cyrus Poonawalla bought 31,57,900 shares of Panacea Biotec at Rs 285.

 
Panacea Biotec Limited - Disclosure under SEBI Takeover Regulations

2018-03-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Panacea Biotec Limited - Outcome of Board Meeting

2018-03-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Panacea Biotec clears US FDA inspection for Baddi formulation facility

2018-03-09 moneycontrol
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.

 
Panacea Biotec clears US FDA inspection for Baddi formulation facility

2018-03-09 moneycontrol
Panacea Biotec on Friday said it has received Establishment Inspection Report (EIR) from US FDA for its Baddi formulation facility in Himachal Pradesh, indicating a formal closure of the inspection.

 
Closing Bell: Sensex, Nifty, Midcap close lower; Tata Steel, Axis Bank top losers

2018-03-09 moneycontrol
3:30 pm Market Closing: Benchmark indices reversed some of previous day's gains amid sell-off in last hour of trade.

 
Panacea Biotec rises 6% on EIR from USFDA for Baddi plant

2018-03-09 moneycontrol
Shares of Panacea Biotec rose 6 percent intraday Friday as it received establishment inspection report (EIR) from USFDA for its Baddi plant.

 
Panacea Biotec Limited - Press Release

2018-03-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Panacea Biotec Limited - Demise

2018-02-22 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
 
Panacea Biotec collaborates with Serum Institute for new hexavalent vaccine for infants

2018-01-22 moneycontrol
Panacea Biotec in focus as the company has collaborated with Serum Institute of India for a new hexavalent vaccine for infants. In an interview with CNBC-TV18, Rajesh Jain, Joint Managing Director of the company discussed about the same.

 
Pharma weekly wrap: Pharma stocks extend loses ahead of Q3 results

2018-01-20 moneycontrol
Pharma stocks extended losses for the second consecutive week, ahead of the announcement of third-quarter results. The overall bullish sentiment prevalent in the stock market didn't rub off on pharma stocks.

 
Panacea Biotech, Serum join hands to take ‘six-in-one’ vaccine global

2018-01-18 thehindubusinessline
Vaccine maker Panacea Biotec has entered into a collaboration with thr Serum Institute of India to take the former's fully liquid six-in-one vaccine onto a global stage, said Rajesh Jain, Panacea's Joint Managing Director.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

21h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

22h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...